

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): ALTMANN, Scott W

Group Art Unit: 1653

Application No.: 10/736769

Examiner: Liu, Samuel W.

Filed: 12/16/2003

Atty. Docket No. : JB01603K3

For: NPC1L1 (NPC3) AND METHODS OF USE THEREOF

X

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450  
 Mail Stop: AMENDMENT  
 Sir:

(a) Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that the documents listed on the accompanying Forms PTO/SB/08a & 08b be considered and made of record in the above-identified patent application. Other than cited U.S. patents and published patent applications, copy(ies) of these documents ☒ are enclosed ☐ were filed in related U.S. Application No(s) \_\_\_\_\_ filed \_\_\_\_\_ respectively. Since the Examiner is believed to have ready access to the cited U.S. patents and published patent applications, copies of these documents are not herewith transmitted, but will be provided upon request.

(b) No fee is believed to be due because:

- ☐ This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); **or**
- ☐ This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.

(c) ☒ This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**

- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **or**
- ☒ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- (d) ☐ This Information Disclosure Statement is being submitted on or before the payment of the issue fee; and:
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **and**
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- ☐ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365.

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case.

Respectfully submitted,

By:



THOMAS A. TRIOLO


Reg. No.: 48001

**Agent of Record**

Telephone No.: 908-298-2347

Dated: July 17, 2006

**Schering-Plough Corporation**  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388



REPLACEMENT SHEET FOR FORM 1449/PTO

ATTY. DOCKET NO.:  
JB01603K3 US

SERIAL NO.:  
10/736,769

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT:  
Altmann *et al.*

FILING DATE:  
December 16, 2003

GROUP:  
1653

(USE AS MANY SHEETS AS NECESSARY)

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	CITE NO. <sup>1</sup>	DOCUMENT NUMBER	PUB. DATE.	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		6,426,198	Jul. 30, 2002	Cartsea <i>et al.</i>	
		US2002/0151536A1	Oct. 17, 2002	Davis <i>et al.</i>	

### FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL	CIT E NO. <sup>1</sup>	DOCUMENT  Country code <sup>3</sup> - number <sup>4</sup> -kind code <sup>5</sup> (if known)	PUB. DATE.	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		WO2006015365(A1)	Feb. 9, 2006	Mount Sinai School of Medicine		
		WO2005/69900	Aug. 4, 2005	Merck & Co.		

Examiner signature:

Date considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

SUBSTITUTE FOR FORM 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE AS MANY SHEETS AS NECESSARY)		ATTY. DOCKET NO.: JB01603K3 US  SERIAL NO.: 10/736,769  APPLICANT: Altmann <i>et al.</i>  FILING DATE: December 16, 2003  GROUP: 1653	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		IOANNOU, Multidrug permeases and subcellular cholesterol transport, Nat Rev Mol Cell Biol. 2001 Sep;2(9):657-68.	
Examiner signature:		Date considered:	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.